SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 6.3% – Time to Buy?

Posted by Francis Steltz on Oct 2nd, 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report)’s stock price traded up 6.3% during trading on Wednesday. The stock traded as high as $12.25 and last traded at $12.2350. 4,092,780 shares traded hands during trading, a decline of 49% from the average daily volume of 8,029,625 shares. The stock had previously closed at $11.51.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SLS. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Stock Report on SLS

SELLAS Life Sciences Group Stock Performance

The stock has a 50 day simple moving average of $12.35 and a two-hundred day simple moving average of $9.43. The firm has a market cap of $2.29 billion, a PE ratio of -53.95 and a beta of 2.56.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Institutional Investors Weigh In On SELLAS Life Sciences Group

Hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC grew its stake in shares of SELLAS Life Sciences Group by 43.1% during the 2nd quarter. Tidal Investments LLC now owns 128,761 shares of the company’s stock worth $1,901,000 after purchasing an additional 38,754 shares during the period. Arizona State Retirement System purchased a new stake in SELLAS Life Sciences Group during the second quarter worth $731,000. Nykredit A S purchased a new stake in SELLAS Life Sciences Group during the second quarter worth $27,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in SELLAS Life Sciences Group during the second quarter valued at $257,000. Finally, Wellington Management Group LLP increased its holdings in SELLAS Life Sciences Group by 73.2% in the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after buying an additional 252,531 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company’s research and development programs are designed to address cancers with significant unmet medical needs.

SELLAS’s lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms’ tumor 1 (WT1), a protein expressed in several types of cancer.